Loading stock data…
CorMedix Inc. (CRMD)
$8.18-0.25 (-2.97%)
Market ClosedLast close Sep 8
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CorMedix Inc. in the Healthcare sector is trading at $8.18 with a market capitalization of $646M. Wall Street consensus targets $15.40 (5 analysts), implying a +88.3% move over the next 12 months. The stock is currently 39% below its 52-week high of $13.48, remaining 0.8% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +88.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $127.43M↓ | $128.62M↑ | $104.28M↑ | $39.74M↑ | $39.08M |
| Gross Profit | $105.12M↓ | $107.31M↑ | $93.08M↑ | $37.87M↑ | $37.48M |
| Operating Income | $63.66M↑ | $59.13M↑ | $51.35M↑ | $19.54M↓ | $20.13M |
| Net Income | $38.60M↑ | $14.02M↓ | $108.56M↑ | $19.83M↓ | $20.64M |
Peer Comparison
JNJUNHPFE
Fundamentals
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$645.66M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.79
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
41.42%
Volume
Today's trading volume
1.10M
Recent News
CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely Budged
On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year’s figure. Management also raised its full year adjusted EBITDA outlook. Yet full year revenue guidance stayed exactly […]
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix (CRMD) Upgraded to Buy: Here's Why
CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
DefenCath revenue hit $66.1M as CorMedix expands dialysis partnerships and advances REZZAYO.
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.